DOCSLIB.ORG

Global Action to Reduce HIV Stigma and Discrimination

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Global Action to Reduce HIV Stigma and Discrimination UCLA UCLA Previously Published Works Title Global Action to reduce HIV stigma and discrimination Permalink https://escholarship.org/uc/item/1vd08478 Journal Journal of the International AIDS Society, 16(3Suppl 2) ISSN 1758-2652 Authors Stangl, Anne L Grossman, Cynthia I Sidibé, Michel et al. Publication Date 2013-11-01 DOI 10.7448/ias.16.3.18934 Peer reviewed eScholarship.org Powered by the California Digital Library University of California CCESS A ONLINE OPEN PEER-REVIEWD ONLINE HIV/AIDS JOURNAL ONLINE CCESS OPEN ACCESS HIV/AIDS JOURNAL PEER-REVIEWD A HIV/AIDS JOURNAL PEER-REVIEWD PEER-REVIEWD PEER-REVIEWDONLINE HIV/AIDS JOURNAL OPEN ACCESS ONLINE PEER-REVIEWDJOURNAL HIV/AIDS ONLINE ONLINE ONLINE ONLINE HIV/AIDS JOURNAL HIV/AIDS JOURNALOPEN ONLINE HIV/AIDS JOURNAL OPEN PEER-REVIEWDJOURNAL HIV/AIDS HIV/AIDS JOURNAL A ONLINE OPEN ACCESS OPEN ACCESS CCESS HIV/AIDS JOURNAL OPEN ACCESS ACCESS HIV/AIDS JOURNAL PEER-REVIEWDONLINE HIV/AIDS JOURNAL OPEN ACCESS CCESS A OPEN PEER-REVIEWDONLINE PEER-REVIEWD PEER-REVIEWD HIV/AIDS JOURNAL HIV/AIDS JOURNALHIV/AIDS JOURNAL PEER-REVIEWD Global action to reduce HIV stigma and discrimination Guest Editors: Anne L. Stangl and Cynthia I. Grossman SHAME DISCRIMINATION KEY POPULATIONS HIV HUMAN RIGHTS DISCRIMINATION STIGMA REDUCTION BLAME KNOWLEDGE HIV BLAME COMMUNITY STIGMA HUMAN RIGHTS MEASURES STIGMA SHAME STRUCTURAL DRIVERS STRUCTURAL ACTION MULTI-LEVEL INTERVENTIONS MULTI-LEVEL RESILIENCE BONE DENSITY Volume 16, Supplement 2 Scan this QR code with your mobile device to view November 2013 the special issue online Support The publication of this supplement was supported by the Stigma Action Network. We are especially grateful to funding from the Joint United Nations Programme on HIV/AIDS, The National Institute of Mental Health, and the STRIVE research programme consortium funded by UKaid from the Department for International Development. Global Action to reduce HIV stigma and discrimination Guest Editors: Anne L Stangl and Cynthia I Grossman Contents Foreword: Global action to reduce HIV stigma and discrimination Michel Sidibé and Eric P Goosby Editorial: Global action to reduce HIV stigma and discrimination Cynthia I Grossman and Anne L Stangl Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis Ingrid T Katz, Annemarie E Ryu, Afiachukwu G Onuegbu, Christina Psaros, Sheri D Weiser, David R Bangsberg and Alexander C Tsai A systematic review of interventions to reduce HIV-related stigma and discrimination from 2002 to 2013: how far have we come? Anne L Stangl, Jennifer K Lloyd, Laura M Brady, Claire E Holland and Stefan Baral Resisting and challenging stigma in Uganda: the role of support groups of people living with HIV Gitau Mburu, Mala Ram, Morten Skovdal, David Bitira, Ian Hodgson, Grace W Mwai, Christine Stegling and Janet Seeley Community-based interventions that work to reduce HIV stigma and discrimination: results of an evaluation study in Thailand Aparna Jain, Ratana Nuankaew, Nungruthai Mongkholwiboolphol, Arunee Banpabuth, Rachada Tuvinun, Pakprim Oranop na Ayuthaya and Kerry Richter Implementing a stigma reduction intervention in healthcare settings Li Li, Chunqing Lin, Jihui Guan and Zunyou Wu Testing the efficacy of an HIV stigma reduction intervention with medical students in Puerto Rico: the SPACES project Nelson Varas-Díaz, Torsten B Neilands, Francheska Cintrón-Bou, Melissa Marzán-Rodríguez, Axel Santos-Figueroa, Salvador Santiago-Negrón, Domingo Marques and Sheilla Rodríguez-Madera A brief, standardized tool for measuring HIV-related stigma among health facility staff: results of field testing in China, Dominica, Egypt, Kenya, Puerto Rico and St. Christopher & Nevis Laura Nyblade, Aparna Jain, Manal Benkirane, Li Li, Anna-Leena Lohiniva, Roger McLean, Janet M Turan, Nelson Varas-Díaz, Francheska Cintrón-Bou, Jihui Guan, Zachary Kwena and Wendell Thomas Access to justice: evaluating law, health and human rights programmes in Kenya Sofia Gruskin, Kelly Safreed-Harmon, Tamar Ezer, Anne Gathumbi, Jonathan Cohen and Patricia Kameri-Mbote Prevalence and drivers of HIV stigma among health providers in urban India: implications for interventions Maria L Ekstrand, Jayashree Ramakrishna, Shalini Bharat and Elsa Heylen Assessment of HIV-related stigma in a US faith-based HIV education and testing intervention Jannette Y Berkley-Patton, Erin Moore, Marcie Berman, Stephen D Simon, Carole Bowe Thompson, Thomas Schleicher and Starlyn M Hawes Reducing shame in a game that predicts HIV risk reduction for young adult men who have sex with men: a randomized trial delivered nationally over the web John L Christensen, Lynn Carol Miller, Paul Robert Appleby, Charisse Corsbie-Massay, Carlos Gustavo Godoy, Stacy C Marsella and Stephen J Read Sexual stigma and discrimination as barriers to seeking appropriate healthcare among men who have sex with men in Swaziland Kathryn Risher, Darrin Adams, Bhekie Sithole, Sosthenes Ketende, Caitlin Kennedy, Zandile Mnisi, Xolile Mabusa and Stefan D Baral Individual-level socioeconomic status and community-level inequality as determinants of stigma towards persons living with HIV who inject drugs in Thai Nguyen, Vietnam Travis Lim, Carla Zelaya, Carl Latkin, Vu Minh Quan, Constantine Frangakis, Tran Viet Ha, Nguyen Le Minh and Vivian Go Volume 16, Supplement 2 November 2013 http://www.jiasociety.org/index.php/jias/issue/view/1464 Sidibe´ M and Goosby EP. Journal of the International AIDS Society 2013, 16(Suppl 2):18893 http://www.jiasociety.org/index.php/jias/article/view/18893 | http://dx.doi.org/10.7448/IAS.16.3.18893 Foreword Global action to reduce HIV stigma and discrimination This JIAS special issue examining HIV-related stigma and discrimination comes at a time when we see overwhelming evidence that global solidarity and shared responsibility are transforming the vision of an AIDS-free generation. A record of 10 million people living with HIV are now receiving treatment, far fewer people are dying from AIDS-related illnesses, 25 countries have reduced new forms of HIV infections by more than 50%, and new HIV treatment and prevention science promise yet more results. Yet, our work is far from over. This is particularly true when it comes to fighting discrimination and stigma. The PEPFAR Blueprint, published last World AIDS Day, provides a roadmap for how we are partnering with countries to achieve an AIDS-free generation, and calls for an end to stigma and discrimination against people living with HIV and key populations. HIV-related stigma and discrimination continues to endanger people living with the virus, and it still prevents millions of people from coming forward for testing and for prevention and treatment services. Some 50Á60% of people living with HIV are unaware of their status. Many others choose to hide it. Communities most affected by the epidemic Á sex workers, people who use drugs, men who have sex with men and transgender people Á remain highly stigmatized. These individuals and their families are often unable to exercise their right to health, non-discrimination and freedom from violence. At the 2011 UN High Level Meeting on HIV/AIDS, Member States committed to the goal of reducing stigma, discrimination and violence related to HIV. It is time to redouble our efforts. Countries must intensify their actions to build effective stigma- reduction programmes and policies; protective laws and protocols; and appropriate legal, social and policy frameworks that will eliminate stigma, discrimination and violence related to HIV. It is a global shared responsibility, and one that includes continued research into causes, manifestations and new metrics and monitoring approaches. This issue of JIAS examines HIV-related stigma in a variety of contexts and settings and explores its impact on several populations, including medical students in Puerto Rico, church leaders in the United States, men who have sex with men in Swaziland and healthcare workers around the world. Ending HIV-related stigma and discrimination will take considerable investment of time and resources, but our commitment is steadfast, and we are grateful to those who keep showing us how to do it better. The rights of all people living with or affected by HIV must be protected. It is that simple. Eric P. Goosby, MD, RADM Michel Sidibe´ Ambassador at Large and US Global AIDS Coordinator Executive Director The President’s Emergency Plan for AIDS Relief Joint United Nations Programme on HIV/AIDS US Department of State 1 Grossman CI and Stangl AL. Journal of the International AIDS Society 2013, 16(Suppl 2):18881 http://www.jiasociety.org/index.php/jias/article/view/18881 | http://dx.doi.org/10.7448/IAS.16.3.18881 Editorial Global action to reduce HIV stigma and discrimination Cynthia I Grossman§,1 and Anne L Stangl2,3 §Corresponding author: Cynthia I Grossman, HIV Care Engagement and Secondary Prevention Program, Division of AIDS Research, National Institutes of Mental Health, 6001 Executive Boulevard, RM 6201, MSC 9619, Bethesda, MD 20892, USA. ([email protected]) Abstract There is no question that the stigma and discrimination associated with HIV and AIDS can be reduced through intervention. The inclusion of stigma and discrimination reduction as a critical component of achieving an AIDS-free generation in recent UNAIDS, UN and PEPFAR political initiatives is promising. Yet national governments need evidence on effective interventions at the individual, community and societal levels in order to strategically incorporate stigma and discrimination
Load more

Recommended publications
  • Global Health Funding Cuts in H.R. 1: Projecting the Human Cost Lives at Stake: in February 2011, the U.S
    February 2011 The Foundation for AIDS Research ISSUE BRIEF Global Health Funding Cuts in H.R. 1: Projecting the Human Cost Lives at Stake: In February 2011, the U.S. House of Representatives passed a Continuing Resolution (H.R. 1) to fund the federal government The Potential Annual Human Impact of through the rest of the fiscal year. The legislation would cut more Reducing Bilateral Global Health than $100 billion from the President’s FY 2011 budget request Funding to H.R. 1 Levels and represents the largest spending reduction in Congressional history. • Funding for AIDS treatment for 448,866 people would be eliminated, resulting in a halt to treatment Global health programs represent a high-impact expansion and deeper cuts in HIV prevention and other areas in an effort to avoid removing current investment, advancing American security, patients from lifesaving treatment. diplomatic, and humanitarian objectives. • 299,294 orphans and vulnerable children could lose their food, education, and livelihood assistance. U.S. investments in global health account for only one-quarter • 20,000 more infants could be infected with HIV of 1% of the U.S. budget and they save literally millions of each year due to reductions in services to combat lives each year. These global health programs (through the mother-to-child HIV transmission. President’s Global Health Initiative, bilateral AIDS funding for PEPFAR, and the Global Fund to Fight AIDS, Tuberculosis • Nearly 3.9 million fewer people would be treated and Malaria) represent a high-impact investment, advancing for malaria and 2 million fewer insecticide-treated American security, diplomatic, and humanitarian objectives.
    [Show full text]
  • Amfar India to Benefit Amfar, the Foundation for AIDS Research
    amfAR India To Benefit amfAR, The Foundation for AIDS Research November 2014 Mumbai, India Event Produced by Andy Boose / AAB Productions A Golden Opportunity amfAR held its inaugural Indian fundraising gala in Mumbai in November 2013. The event was hosted by amfAR Global Fundraising Chairman Sharon Stone, and Bollywood stars Aishwarya Rai Bachchan and Abhishek Bachchan. It was chaired by amfAR Chairman Kenneth Cole, Vikram Chatwal, Anuj Gupta, Rocky Malhotra, and Hilary Swank. Memorable Moments The black-tie event, presented by Dr. Cyrus Poonawalla and held at The Taj Mahal Palace Hotel, featured a cocktail reception, dinner, and an exquisite gold-themed fashion show that showcased three of India’s most important fashion designers -- Rohit Bal, Abu Jani- Sandeep Khosla, and Tarun Tahiliani. The evening concluded with a spirited performance by pop sensation Ke$ha, whose Hilary Swank for amfAR India songs included her hits Animal, We R Who We R, and Tik Tok. Among the Guests Neeta Ambani, Torquhil Campbell, Duke of Argyll, Sonal Chauhan, Venugopal Dhoot, Nargis Fakhri, Sunil Gavaskar, Parmeshwar Godrej, Lisa Haydon, Dimple Kapadia, Tikka Kapurthala, Nandita Mahtani, Rocky The Love Gold Fashion Show for amfAR India Abhishek Bachchan, Sharon Stone, Nita Ambani, and Aishwarya Rai Bachchan for amfAR India Malhotra, Dino Morea, among many others. Kenneth Cole and Sharon Stone for amfAR India Total Media Impressions: 2.4 Billion Total Media Value: $1.6 Million Aishwarya Rai Bachchan for amfAR India The Love Gold Fashion Show for amfAR India A Star-Studded Cast amfAR’s fundraising events are world renowned for their ability to attract a glittering list of top celebrities, entertainment industry elite, and international society.
    [Show full text]
  • Relationality and Masculinity in Superhero Narratives Kevin Lee Chiat Bachelor of Arts (Communication Studies) with Second Class Honours
    i Being a Superhero is Amazing, Everyone Should Try It: Relationality and Masculinity in Superhero Narratives Kevin Lee Chiat Bachelor of Arts (Communication Studies) with Second Class Honours This thesis is presented for the degree of Doctor of Philosophy of The University of Western Australia School of Humanities 2021 ii THESIS DECLARATION I, Kevin Chiat, certify that: This thesis has been substantially accomplished during enrolment in this degree. This thesis does not contain material which has been submitted for the award of any other degree or diploma in my name, in any university or other tertiary institution. In the future, no part of this thesis will be used in a submission in my name, for any other degree or diploma in any university or other tertiary institution without the prior approval of The University of Western Australia and where applicable, any partner institution responsible for the joint-award of this degree. This thesis does not contain any material previously published or written by another person, except where due reference has been made in the text. This thesis does not violate or infringe any copyright, trademark, patent, or other rights whatsoever of any person. This thesis does not contain work that I have published, nor work under review for publication. Signature Date: 17/12/2020 ii iii ABSTRACT Since the development of the superhero genre in the late 1930s it has been a contentious area of cultural discourse, particularly concerning its depictions of gender politics. A major critique of the genre is that it simply represents an adolescent male power fantasy; and presents a world view that valorises masculinist individualism.
    [Show full text]
  • Columbia Global Centers Amman 2015 Annual
    “Rather than observing world events from a distance, our students and faculty who A Message from Lee C. Bollinger travel to the global centers With the opening of global centers in Amman and Beijing in 2009, Columbia began an initiative that has become central to our understanding of what it means to be a global university. Amman and Beijing have been joined by six additional Columbia Global Centers, producing a network across four continents that is bringing together great find themselves immersed minds from diverse backgrounds to meet the challenges of our time. in those events and learning The potential of the Columbia Global Centers to provide the intellectual leadership for addressing their regions’ daunting challenges was apparent from the outset. With each passing year, more and more of that potential is being realized, and the results have been gratifying and at times inspiring. The pages of this report set forth those in unique ways from the achievements. All who know the Amman Center are well aware that this growth would not have occurred without the steadfast support of so many. Professor Safwan Masri, Columbia’s Executive Vice President for Global Centers experience.” and Global Development, deserves recognition for his role, as well. At the Columbia Global Centers, Columbia students and faculty are encountering some of the leading figures from Lee C. Bollinger every corner of the globe: innovative scholars, former heads of state, government officials, policy makers, and leaders of industry. This past year, each center hosted a rich variety of programs and events: from workshops assessing the President, Columbia University impact of the refugee crisis on global public health in Amman, to lectures on immigration and African-American cinema in Rio de Janeiro, to panels on women’s rights in Beijing and many more.
    [Show full text]
  • Bob Iger Kevin Mayer Michael Paull Randy Freer James Pitaro Russell
    APRIL 11, 2019 Disney Speakers: Bob Iger Chairman and Chief Executive Officer Kevin Mayer Chairman, Direct-to-Consumer & International Michael Paull President, Disney Streaming Services Randy Freer Chief Executive Officer, Hulu James Pitaro Co-Chairman, Disney Media Networks Group and President, ESPN Russell Wolff Executive Vice President & General Manager, ESPN+ Uday Shankar President, The Walt Disney Company Asia Pacific and Chairman, Star & Disney India Ricky Strauss President, Content & Marketing, Disney+ Jennifer Lee Chief Creative Officer, Walt Disney Animation Studios ©Disney Disney Investor Day 2019 April 11, 2019 Disney Speakers (continued): Pete Docter Chief Creative Officer, Pixar Kevin Feige President, Marvel Studios Kathleen Kennedy President, Lucasfilm Sean Bailey President, Walt Disney Studios Motion Picture Productions Courteney Monroe President, National Geographic Global Television Networks Gary Marsh President & Chief Creative Officer, Disney Channel Agnes Chu Senior Vice President of Content, Disney+ Christine McCarthy Senior Executive Vice President and Chief Financial Officer Lowell Singer Senior Vice President, Investor Relations Page 2 Disney Investor Day 2019 April 11, 2019 PRESENTATION Lowell Singer – Senior Vice President, Investor Relations, The Walt Disney Company Good afternoon. I'm Lowell Singer, Senior Vice President of Investor Relations at THe Walt Disney Company, and it's my pleasure to welcome you to the webcast of our Disney Investor Day 2019. Over the past 1.5 years, you've Had many questions about our direct-to-consumer strategy and services. And our goal today is to answer as many of them as possible. So let me provide some details for the day. Disney's CHairman and CHief Executive Officer, Bob Iger, will start us off.
    [Show full text]
  • Antiretroviral Drug-Related Liver Mortality Among HIV-Positive
    HIV/AIDS MAJOR ARTICLE Antiretroviral Drug-Related Liver Mortality Among HIV-Positive Persons in the Absence of Hepatitis B or C Virus Coinfection: The Data Collection on Adverse Events of Anti-HIV Drugs Study Helen Kovari,1 Caroline A. Sabin,2 Bruno Ledergerber,1 Lene Ryom,3 Signe W. Worm,3 Colette Smith,2 Andrew Phillips,2 Peter Reiss,4 Eric Fontas,5 Kathy Petoumenos,6 Stéphane De Wit,7 Philippe Morlat,8 Jens D. Lundgren,3 and Rainer Weber1 1Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland; 2Research Department of Infection and Population Health, Division of Population Health, Royal Free and University College, London, United Kingdom; 3Copenhagen HIV Programme, University of Copenhagen, Denmark; 4HIV Monitoring Foundation, Academic Medical Center, Amsterdam, The Netherlands; 5Département de Santé Publique, Centre Hospitalier Universitaire, Nice, France; 6National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia; 7Department of Infectious Diseases, St Pierre University Hospital, Brussels, Belgium; and 8Service de Medicine Interne et Maladies Infectieuses, Hopital Saint-André, CHU de Bordeaux, France Background. Liver diseases are the leading causes of death in human immunodeficiency virus (HIV)–positive persons since the widespread use of combination antiretroviral treatment (cART). Most of these deaths are due to hepatitis C (HCV) or B (HBV) virus coinfections. Little is known about other causes. Prolonged exposure to some antiretroviral drugs might increase hepatic mortality. Methods. All patients in the Data Collection on Adverse Events of Anti-HIV Drugs study without HCV or HBV coinfection were prospectively followed from date of entry until death or last follow-up.
    [Show full text]
  • CD4:CD8 Ratio Comparison Between Cohorts of HIV-Positive Asians and Caucasians Upon Commencement of Antiretroviral Therapy
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Antivir Manuscript Author Ther. Author manuscript; Manuscript Author available in PMC 2018 May 03. Published in final edited form as: Antivir Ther. 2017 ; 22(8): 659–668. doi:10.3851/IMP3155. CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy Kathy Petoumenos1, Jun Yong Choi2, Jennifer Hoy3, Sasisopin Kiertiburanakul4, Oon Tek Ng5, Mark Boyd6, Reena Rajasuriar7,8, and Matthew Lawon1 on behalf of the Australian HIV Observational Database and the TreatAsia HIV Observational Database 1The Kirby Institute, UNSW Australia, UNSW Sydney NSW 2052, Australia 2Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea 3Department of Infectious Diseases, The Alfred Hospital and Monash University, Melbourne, Australia 4Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand 5Department of Infectious Disease and Communicable Disease Centre, Tan Tock Seng Hospital, Singapore, Singapore 6University of Adelaide, Adelaide, South Australia 5005, Australia 7Centre of Excellence for Research in AIDS (CERiA), University of Malaya, Kuala Lumpur, Malaysia 8Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia Abstract Background—In the era of effective antiretroviral treatment (ART) CD4:CD8 ratio is proposed as a potential marker for HIV-positive (HIV+) patients at increased risk for non-AIDS comorbidities. The current study aims to compare CD4:CD8 ratio between Asian and Caucasian HIV+ patients. Methods—HIV+ patients from the Australian HIV Observational Database (AHOD) and the TREAT Asia HIV Observational Database (TAHOD) meeting specific criteria were included. In these analyses Asian and Caucasian status were defined by cohort.
    [Show full text]
  • ISSUE BRIEF AIDS Research: Broad Health and Economic Benefits
    The Foundation for AIDS Research July 2011 ISSUE BRIEF AIDS Research: Broad Health and Economic Benefits Investments in health research at the National Institutes of Health (NIH) have paid enormous dividends in the health and well-being of people in the U.S. and around the world. HIV and AIDS research supported by NIH has yielded important recent advances and holds great promise for significantly reducing HIV infection rates and providing more effective treatments for people living with HIV/AIDS. Yet years of erratic funding levels for NIH and declining purchasing power have undermined our nation’s leadership in health research and our scientists’ ability to take advantage of the expanding opportunities to advance healthcare. The race to find better treatments and cures for cancer, heart Funding for AIDS and overall NIH health research, FY2003–FY2011, in current and inflation-adjusted dollars. The red lines show funding in disease, AIDS, and other diseases—and to control global constant 2003 dollars and show the progressive loss of purchasing power epidemics such as AIDS, tuberculosis, and malaria—depends for AIDS and overall health research funding. (Source: Office of AIDS on robust long-term investment in health research at NIH. Research, National Institutes of Health) Extraordinary Accomplishments in AIDS Research The U.S. has been the global leader in research to prevent and 1982: Scientists name a new disease, acquired treat HIV/AIDS and related serious health conditions. Over the immune deficiency syndrome (AIDS), a year after its past decades, the comprehensive AIDS research program at the discovery. NIH has led to scientific advances that have saved the lives of millions of people with HIV/AIDS and prevented millions more from 1984: American and French scientists confirm that becoming infected.
    [Show full text]
  • Financial Statements Together with Report of Independent Certified Public Accountants
    Financial Statements Together with Report of Independent Certified Public Accountants THE FOUNDATION FOR AIDS RESEARCH (formerly known as The American Foundation for AIDS Research) September 30, 2019 and 2018 Contents Page Report of Independent Certified Public Accountants 3 Financial Statements Statements of Financial Position as of September 30, 2019 and 2018 5 Statements of Activities for the years ended September 30, 2019 and 2018 6 Statement of Functional Expenses for the year ended September 30, 2019 7 Statement of Functional Expenses for the year ended September 30, 2018 8 Statements of Cash Flows for the years ended September 30, 2019 and 2018 9 Notes to the Financial Statements 10 GRANT THORNTON LLP REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS 757 Third Ave., 9th Floor New York, NY 10017-2013 D 212 599 0100 F 212 370 4520 S linkd.in/grantthorntonus To the Board of Trustees of twitter.com/grantthorntonus The Foundation for AIDS Research: We have audited the accompanying financial statements of The Foundation for AIDS Research (a New York not-for-profit corporation, also known as “amfAR”), which comprise the statements of financial position as of September 30, 2019 and 2018, and the related statements of activities, functional expenses and cash flows for the years then ended, and the related notes to the financial statements. Management’s responsibility for the financial statements Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.
    [Show full text]
  • Approaching a Cure for AIDS Defining an AIDS Cure
    Approaching a Cure for AIDS Jeffrey Laurence, M.D. Senior Scientific Consultant for Programs, amfAR Professor of Medicine, Weill Cornell Medical College www.amfar.org www.amfar.org Defining an AIDS Cure Definition: “Treat a disease such that the patient no longer needs to continue treatment, as opposed to suppression or management of the disease as is presently required in diabetes, rheumatoid arthritis, and HIV.” * Specific: Functional vs. sterilizing cures *Fauci A. XVIIth International AIDS Conference, www.amfar.org Mexico City, Aug 3-8, 2008, Abst WESS0101 1 We want to cure HIV. “Viruses can’t be cured.” “Viruses can’t be cured…so far” •In 2009, NIAID spent $41million on HIV cure research, 3% of budget •(~$600million spent on vaccine research) •amfAR filling the gaping hole www.amfar.org A Cure for AIDS •AS Fauci: “We need a cure for AIDS.”* •ART is a life-long commitment •Current ART, and likely every newly developed antiretroviral drug, will have long-term, potentially life-limiting, adverse effects •2.7 million people were newly HIV infected in 2007, with ART reaching only 30% of those who needed it •It is unlikely that we can treat our way out of this pandemic: For every person started on ART, 2-3 are newly infected *Fauci A. XVIIth International AIDS Conference, www.amfar.org Mexico City, Aug 3-8, 2008, Abst WESS0101 2 “The U.S. spends about $20 billion every year on AIDS (both for programs in the U.S. and globally). The money is keeping millions of people alive around the world and preventing millions of infections.
    [Show full text]
  • US Philanthropic Support to HIV-AIDS in 2007
    07 FUNDERS U.S. Philanthropic Support to Address HIV/AIDS in 2007 CONCERNED ABOUT AIDS Acknowledgements FCAA wishes to thank UNAIDS for its very generous funding and in-kind support of this publication. The data, findings, and conclusions presented in this report are those of FCAA alone and do not necessarily reflect the perspectives or the opinions of UNAIDS, or any other funder. FCAA also gratefully acknowledges the efforts of the following people in ensuring the quality and comprehensiveness of this report: l FCAA Board members Anu Gupta of Johnson & Johnson, Mark Ishaug of AIDS Foundation of Chicago, and Jennifer Kates of The Henry J. Kaiser Family Foundation l Jose Antonio Izazola of UNAIDS, and Astrid Bonfield of the European HIV/AIDS Funders Group (EFG) and The Diana, Princess of Wales Memorial Fund l Jacob Gayle of the Ford Foundation FCAA thanks all the philanthropic entities who responded to the 2007 FCAA resource tracking survey that provided the bulk of information for this publication. Thanks also to Foundation Center and Foundation Search for use of their data to supplement this report. Finally, FCAA thanks all the funding institutions that supported us with a membership contribution in 2008 — our work to build community in HIV/AIDS philanthropy would not be possible without your support. U.S. Philanthropic Support to Address HIV/AIDS in 2007 Table of Executive Summary Contents 2 Executive Summary Total HIV/AIDS-related philanthropy among U.S.-based funders increased between 2006 and 2007, continuing the trend of the last several years. Estimated HIV/AIDS-related funding disbursements by 4 About FCAA and U.S.-based philanthropies grew from $504 million in 2006 to $555 million in 2007, a 10% increase.
    [Show full text]
  • Generationcure Annual Events
    generationCURE Annual Events Sponsorship Opportunities for 2013-2014 About amfAR amfAR, The Foundation for AIDS Research, is dedicated to ending the HIV/AIDS epidemic through innovative research. With the freedom and flexibility to respond quickly to emerging areas of scientific promise, amfAR plays a catalytic role in accelerating the pace of HIV/AIDS research and achieving real breakthroughs. amfAR-funded research has increased our understanding of HIV and has helped lay the groundwork for major advances in the treatment and prevention of HIV/AIDS. Since 1985, amfAR has invested more than $366 million in its mission and has awarded grants to more than 2,000 research teams worldwide. About generationCURE In the fall of 2011, a small group of young professionals from the fields of finance, art, media, and entertainment came together to form generationCURE: a committee of young people dedicated to helping amfAR accelerate its search for a cure for HIV/AIDS by grooming the next, and hopefully the last, generation of HIV/AIDS champions. Since 2012, the committee has raised more than $90,000 toward their $150,000 goal—the cost of a new, cure-focused research project—through fundraising events on both coasts. About our supporters generationCURE events attract successful young professionals who “socialize with a conscience,” a highly desirable demographic. Each of our events is attended by 200 guests from a wide variety of industries, among them fashion, finance, media, law, and entertainment. Research shows that an association with leading nonprofit organizations such as amfAR makes good business sense. A Cone Corporate Citizenship study has shown that eight out of 10 Americans say that corporate support of good causes wins their trust in a company.
    [Show full text]